
CSL Delivers $2.9 Billion Profit, 110 Million Flu Vaccine Doses
Australian biotech giant CSL delivered a multi-billion dollar profit in the 2024 financial year and a major boost in revenue. The plasma collection, therapeutic, and vaccine company reported an underlying net profit after tax and amortisation (NPATA) of US$2.91 billion (A$4.4 billion) for the 12 months ended June 30, up 11 percent (pdf). CSL’s revenue also soared 11 percent to US$14.8 billion. CSL reported a total full year dividend of US$2.64 per share, up 12 percent on 2023. The global biotechnology company employs more than 32,000 people and delivers products to 100 nations around the world. It is divided into three major divisions—CSL Behring which delivers biotherapies and plasma collection, CSL Seqirus which develops vaccines, and CSL Vifor which focusses on iron deficiency therapies....
